Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Integrating HER2-Directed ADCs Across Early and Metastatic Breast Cancer: Practical Strategies for Testing, Sequencing, and Patient-Centered Care

Clinical Thought

Experts answer your questions related to the program, Integrating HER2-Directed ADCs Across Early and Metastatic Breast Cancer: Practical Strategies for Testing, Sequencing, and Patient-Centered Care. This social media forum provides ongoing access to expert perspectives on challenging cases and practical questions related to HER2-positive and HER2-expressing breast cancer throughout the certified life of the program.

Released: May 28, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Target Audience

This activity is intended for oncologists, advanced practice providers, pharmacists, nurse practitioners, clinical nurse specialists, nurses, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply current evidence and guideline principles to select and sequence HER2-directed therapies across early-stage and metastatic breast cancer 

  • Interpret evolving data on HER2-directed ADCs and integrate key findings into individualized treatment planning for patients with HER2-positive and HER2-expressing disease

Disclosure

Primary Author
Sara A. Hurvitz, MD, FACP: consultant/advisor: Akari, ALX Oncology, Bayer, BeiGene, BeOne, Blueprint, Boundless Bio, BriaCell, BridgeBio, Bristol Myers Squibb, Daiichi Sankyo, Ellipses, EMBioSys, Gilead, Jazz, Lilly Oncology, Luminate, Mersana, Myricx, Prelude Therapeutics, Roche; researcher: AstraZeneca/Daiichi Sankyo, Novartis, Stemline/Menarini; data and safety monitoring board: Alliance Foundation, InClin/Atossa, Quantum Leap, Roche; stocks: ROMTech; other financial or material support: AstraZeneca, Gilead.

Ian Krop, MD, PhD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, EMD Serono, Genentech, Puma, Seagen.

Adrienne G. Waks, MD: consultant/advisor/speaker: AstraZeneca, Genentech, Jazz, Johnson & Johnson, Pfizer; research (support to institution): Genentech, Gilead, Merck, TerSera.